The rationale for this is not new; DLL4, like VEGF, is targeted to disrupt tumor angiogenesis, with an intent to prevent further tumor growth and/or improve delivery of alternative therapeutics through normalized tumor vasculature (136–139). The gene discussed is DLL4; the disease is neoplasm.